Advertisement

Sign up for our newsletter

Advertisement

Tom Pidcock takes race lead in Baby Giro d'Italia after solo stage win

Joe Robinson
2 Sep 2020

The 21-year-old is impressing at the under-23 Giro after victory on Stage 4

Tom Pidcock has taken the race lead in the 'Baby Giro d'Italia' after winning stage four on Tuesday.

The 21-year-old Yorkshireman took an impressive solo victory on the 159.6km mountain stage from Bonferraro di Sorga to Bolca as he rolled home 22 seconds ahead of 20-year-old Italian Kevin Colleoni on a tough uphill finish.

Pidcock raced aggressively on the penultimate climb of the day, La Colina, before attacking the final ascent to Bolca with 3km remaining. Quickly establishing a 30-second lead, he managed to hold off the pursuers to take the race lead with four stages remaining.

Pidcock now leads Colleoni on General Classification by 58 seconds while 21-year-old Giovanni Aleotti sits third overall at 1 minute, 15 seconds. 

It was a just reward for the Trinity Racing Team rider who took second on Stage 3 into Mordano, losing a reduced bunch sprint to 21-year-old Luca Colnaghi.

Pidcock will now have his work cut out to defend his 58 second lead considering the tough stages remaining. Wednesday and Thursday's stages should be decided by bunch sprints while the final two stages in the mountains will likely decide the race overall.

Stage 7 will conclude with a summit finish on the stunning Montespluga, a mammoth 28.2km climb at 5.7 per cent in the Lombardy region, while Stage 8 will see the race conclude in Aprica with a visit to the Passo del Mortirolo earlier in the day.

Whether Pidcock will be able to defend the race lead in the high mountain is unknown but his success yesterday is only reaffirming his progression as one of Britain's most exciting cycling prospects across multiple disciplines.

In February, Pidcock finished second in the elite cyclocross World Championships behind Mathieu van der Poel. Last month, Pidcock also took fourth in the under-23 European Championships time trial.

Read more about: